September 13, 2018
Announcement from Gilead Sciences and Precision BioSciences on a Collaboration to Develop Therapies Against Hepatitis B Virus
“Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
An estimated 257 million people are living with HBV infection around the world. Current HBV treatments suppress HBV viral replication but do not completely clear the virus. The presence of covalently closed circular DNA (cccDNA) enables HBV replication if treatment is stopped. Preliminary studies at Gilead using ARCUS nucleases to target HBV cccDNA in vitro have demonstrated significant activity against cccDNA and integrated HBV DNA in human hepatocytes.”
The collaboration terms for Precision are they will effectively be responsible for the development, formulation, and preclinical evaluation of the investigational nucleases. Gilead is responsible for the clinical development and commercialization of potential therapies. Gilead will additionally fully fund the research and development. Precision, eligible to receive milestone payments of up to an aggregate of $445 million as well as tiered royalties that go up to the mid-teens for commercial products developed through the collaboration.
[Originally posted by PrecisionBiosciences — September 12, 2018]